Literature DB >> 10581363

Comparative aspects of the function and mechanism of SUR1 and MDR1 proteins.

K Ueda1, M Matsuo, K Tanabe, K Morita, N Kioka, T Amachi.   

Abstract

ATP-binding cassette (ABC) superfamily proteins have divergent functions and can be classified as transporters, channels, and receptors, although their predicted secondary structures are very much alike. Prominent members include the sulfonylurea receptor (SUR1) and the multidrug transporter (MDR1). SUR1 is a subunit of the pancreatic beta-cell K(ATP) channel and plays a key role in the regulation of glucose-induced insulin secretion. SUR1 binds ATP at NBF1, and ADP at NBF2 and the two NBFs work cooperatively. The pore-forming subunit of the pancreatic beta-cell K(ATP) channel, Kir6.2, is a member of the inwardly rectifying K(+) channel family, and also binds ATP. In this article, we present a model in which the activity of the K(ATP) channel is determined by the balance of the action of ADP, which activates the channel through SUR1, and the action of ATP, which stabilizes the long closed state by binding to Kir6.2. The concentration of ATP could also affect the channel activity through binding to NBF1 of SUR1. MDR1, on the other hand, is an ATP-dependent efflux pump which extrudes cytotoxic drugs from cells before they can reach their intracellular targets, and in this way confers multidrug resistance to cancer cells. Both NBFs of MDR1 can hydrolyze nucleotides, and their ATPase activity is necessary for drug transport. The interaction of SUR1 with nucleotides is quite different from that of MDR1. Variations in the interactions with nucleotides of ABC proteins may account for the differences in their functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581363     DOI: 10.1016/s0005-2736(99)00157-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism.

Authors:  H W van Veen; A Margolles; M Müller; C F Higgins; W N Konings
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 2.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

3.  Intracellular ATP increases capsaicin-activated channel activity by interacting with nucleotide-binding domains.

Authors:  J Kwak; M H Wang; S W Hwang; T Y Kim; S Y Lee; U Oh
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

4.  Distinct functions and cooperative interaction of the subunits of the transporter associated with antigen processing (TAP).

Authors:  J T Karttunen; P J Lehner; S S Gupta; E W Hewitt; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

5.  ATP hydrolysis-dependent conformational changes in the extracellular domain of ABCA1 are associated with apoA-I binding.

Authors:  Kohjiro Nagao; Kei Takahashi; Yuya Azuma; Mie Takada; Yasuhisa Kimura; Michinori Matsuo; Noriyuki Kioka; Kazumitsu Ueda
Journal:  J Lipid Res       Date:  2011-10-25       Impact factor: 5.922

Review 6.  Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.

Authors:  Suneet Shukla; Zhe-Sheng Chen; Suresh V Ambudkar
Journal:  Drug Resist Updat       Date:  2012-02-09       Impact factor: 18.500

Review 7.  Pharmacogenetics of glucose-lowering drug treatment: a systematic review.

Authors:  Ozlem Bozkurt; Anthonius de Boer; Diederick E Grobbee; Eibert R Heerdink; Huib Burger; Olaf H Klungel
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism.

Authors:  Ritika R Kapoor; Sarah E Flanagan; Ved Bhushan Arya; Julian P Shield; Sian Ellard; Khalid Hussain
Journal:  Eur J Endocrinol       Date:  2013-03-15       Impact factor: 6.664

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.